Group of NSAIDs including glafenine, antrafenine, floctafenine, and the fenamates (mefenamic acid, flufenamic, etofenamic and meclofenamic acids).
Glafenine: 1/2000 to 3,4/100 000 courses. 14 cases of allergy requiring hospital admission in the Netherlands in 1981.
Antrafenine: 1.3/100 000 treatments.
Floctafenine: 0.6/100 000 treatments.
Intolerance to other NSAIDs.
Renal failure, hepatitis, blood dyscrasias.
One case of positive intradermal skin test with glafenine 0.1 to 1 mg/ ml and meclofenamate 0.1 to 1 mg/ ml.
Leukocyte migration test: positive in 50% of patients with glafenine intolerance.
Basophil histamine release: positive in 16% of patients with glafenine intolerance.
Double blind placebo-controlled challenge.
IgE-mediated hypersensitivity: one case reported with positive skin tests in a patient specifically allergic to anthralinic derivatives but tolerating aspirin and other NSAIDs.
Intolerance: similar mechanisms to other NSAIDs.
Avoidance of glafenine and related molecules (withdrawn in numerous countries).
Ascertain other NSAID tolerance.